Elsewhere in this Drug Review Profile, the Pink Sheet examines how the US Food and Drug Administration took the Omicron variant's predominance into account in its review and January approval of Moderna, Inc.'s COVID-19 vaccine Spikevax.(Also see "COVID-19 Vaccines: Spikevax Review Reflected Changing Realities Of Omicron In US" - Pink Sheet, 4 May, 2022.)
Below is the clinical development review timeline and a table of the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?